Abstract
Within the European Community (EC), an EC guideline currently regulates drug development, which I prefer to call good clinical regulatory practice (GCRP) rather than good clinical practice (GCP). With the increased globalization of the pharmaceutical industry, the European Commission is currently reviewing the guideline, and debating whether to issue a directive. This paper looks at the issues involved. Whatever form the regulation takes, it is hoped that GCP at its best will allow submission of summarized data, facilitating regulation and scientific assessment. EC policy should be centered on patient safety, high-quality research, and developing new medicines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
